Related Experiment Video

Updated: Oct 6, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Nandrolone-Induced Tumor Progression in Hormone-Sensitive Prostate Cancer

Shikha Goyal1, Renu Madan1, Narendra Kumar1

  • 1From the Departments of Radiotherapy and Oncology.

Clinical Nuclear Medicine
|January 19, 2022
PubMed

Insights

Anabolic steroids like nandrolone may counteract testosterone suppression in prostate cancer patients undergoing androgen deprivation therapy. This case highlights the risk of rapid cancer progression when using such substances alongside treatment.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Hormone-sensitive prostate cancer (HSPC) treatment relies on suppressing testosterone.
  • Gonadotropin-releasing hormone (GnRH) analogs and antagonists are standard for androgen deprivation therapy (ADT).
  • Anabolic steroids theoretically can oppose ADT's effects.

Purpose of the Study:

  • To report a case of recurrent HSPC with rapid progression during ADT.
  • To investigate the potential impact of anabolic steroid use on ADT efficacy.

Main Methods:

  • A patient with recurrent HSPC on degarelix (GnRH antagonist) for ADT was observed.
  • The patient's medical history, including the use of over-the-counter nandrolone injections, was reviewed.

Main Results:

  • The patient experienced rapid prostate cancer progression despite receiving degarelix therapy.
  • This progression occurred after the initiation of nandrolone injections.

Conclusions:

  • Over-the-counter anabolic steroid use, such as nandrolone, may accelerate progression in hormone-sensitive prostate cancer patients undergoing ADT.
  • Clinicians should be vigilant about potential anabolic steroid use in patients with recurrent prostate cancer receiving ADT.

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.6K
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

25.5K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K